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Abstract
Background:  Consumption of edible mushrooms has been suggested to improve health. A
number of isolated mushroom constituents have been shown to modulate immunity. Five
commonly consumed edible mushrooms were tested to determine whether whole mushrooms
stimulate the immune system in vitro and in vivo.
Results: The white button (WB) extracts readily stimulated macrophage production of TNF-α.
The crimini, maitake, oyster and shiitake extracts also stimulated TNF-α production in macrophage
but the levels were lower than from WB stimulation. Primary cultures of murine macrophage and
ovalbumin (OVA) specific T cells showed that whole mushroom extracts alone had no effect on
cytokine production but co-stimulation with either lipopolysacharide or OVA (respectively)
induced TNF-α, IFN-γ, and IL-1β while decreasing IL-10. Feeding mice diets that contained 2% WB
mushrooms for 4 weeks had no effect on the ex vivo immune responsiveness or associated toxicity
(changes in weight or pathology of liver, kidney and gastrointestinal tract). Dextran sodium sulfate
(DSS) stimulation of mice that were fed 1% WB mushrooms were protected from DSS induced
weight loss. In addition, 2% WB feeding protected the mice from transient DSS induced colonic
injury. The TNF-α response in the colon and serum of the DSS challenged and 2% WB fed mice
was higher than controls.
Conclusion: The data support a model whereby edible mushrooms regulate immunity in vitro. The
in vivo effects of edible mushrooms required a challenge with DSS to detect small changes in TNF-
α and transient protection from colonic injury. There are modest effects of in vivo consumption of
edible mushrooms on induced inflammatory responses. The result is not surprising since it would
certainly be harmful to strongly induce or suppress immune function following ingestion of a
commonly consumed food.
Background
There are thousands of different mushroom species and
about 700 species have been reported to have significant
pharmacological properties [1,2]. Medicinal mushrooms
have a long history of use in traditional Oriental thera-
pies. Hot-water-soluble fractions of medicinal mush-
rooms have been used as medicine in the Far East [3]. In
addition, mushroom extracts have begun to be sold as die-
tary supplements with a world-wide market value of
around 5–6 billion US dollars per year [4].
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Isolated mushroom constituents have been shown to
have beneficial effects on experimental cancer. Efforts
have been made to isolate and purify the active and pro-
tective components of mushrooms. Many of these com-
pounds are large polysaccharides or β-(1→6)-branched β-
(1→3)-linked glucans. The β-glucans have been shown to
inhibit tumor growth in vitro and in vivo. The β-glucans
lentinan from Lentinus edodes, schizophyllan (sonifilan)
from Schizophyllum commune, grifolan from Grifola fron-
dosa, and extracts from Sclerotinia sclerotiorum all have
anti-tumor activity. Intratumor injection of an acid-
treated fraction of Agaricus blazei inhibited tumor growth
of that tumor as well as other tumors at remote sites [5].
An extract from the Phellinus rimosus mushroom extended
the life span of mice by 96% following injection of tumor
cells in an experimental Dalton's lymphoma ascites
model [6]. Injection of a methanol crude extract from
Lepista inversa also increased life span by 50% in a lym-
phocyte leukemia model [7]. Extracts of multiple varieties
of mushrooms have been shown to be protective in exper-
imental cancer models; presumably because in part they
boost anti-tumor immunity. Whether these same benefits
of mushrooms can be derived from whole mushrooms
instead of the isolated components is not known.
There is considerable information and research on identi-
fying the biologically active components of medicinal
mushrooms and using them as therapies and immune sys-
tem modulators. What is less clear is whether the active
components of edible mushrooms are present in ade-
quate amounts to show benefits when consuming whole
mushrooms or using extracts from whole mushrooms in
vitro. Furthermore, there are concerns about the toxico-
logic side effects of whole mushrooms especially the Agar-
icus species that might counter-indicate recommending
eating mushrooms. The aims of the present study were 1)
to determine what the effects of whole mushroom extracts
were on the cytokine profile of macrophage and T cell cul-
tures in vitro, 2) to determine whether feeding mice diets
that contained 1–2% whole mushrooms resulted in meas-
urable changes in immunity, and 3) to determine whether
2% whole mushrooms diets led to pathologic findings in
tissues likely to be affected (liver, kidney, gastrointestinal
tract).
Results
Induction of tumor necrosis factor (TNF)-α in RAW 264.7 
cells by extracts of commonly consumed mushrooms
The mouse macrophage cell line (RAW 264.7) was treated
with mushroom extract (100 μg/ml) or the vehicle
DMSO. Cell viability was high following treatment (90–
95%). Lipopolysacharide (LPS) was used as a positive
control to induce production of TNF-α from RAW cells.
The white button (WB) mushroom extracts readily stimu-
lated TNF-α production from RAW 264.7 cells at levels
comparable to the LPS stimulated cells (Fig. 1). The
crimini, maitake, oyster and shiitake extracts all stimu-
lated TNF-α production from the RAW 264.7 cells; how-
ever, the amount of TNF-α produced was significantly less
than stimulation with the WB mushroom extracts (Fig. 1).
Mushroom regulated cytokine production in bone marrow 
derived macrophage (BMDM)
Follow up experiments used macrophage isolated from
the bone marrow (BM) of wildtype (WT) mice. The data
from WB mushroom extracts is shown since the highest
TNF-α secretion from RAW 264.7 cells was found in the
WB stimulated cultures (Fig. 1). The BMDM cells are
untransformed mouse macrophage that produce a variety
of cytokines. Three cytokines produced by macrophage
were picked for analysis: TNF-α, interleukin (IL)-10 and
IL-1β (Fig. 2). BMDM cells plus DMSO (control) cultures
did not produce TNF-α, IL-10 or IL-1β (data not shown).
Like the results from the RAW 264.7 cell line, WB extracts
alone stimulated TNF-α production. LPS stimulation also
induced TNF-α and the combined effect of WB plus LPS
was additive for TNF-α secretion (Fig. 2A). For IL-1β pro-
duction, WB stimulation alone had no effect, LPS stimu-
lation alone induced IL-1β and WB plus LPS increased the
secretion of IL-1β (Fig. 2B). WB stimulation induced a
small amount of IL-10, while LPS stimulated a robust IL-
10 response and interestingly enough WB addition to the
LPS containing cultures inhibited IL-10 production (Fig.
2C). BMDM were also treated with crimini and shiitake
extracts and the results were similar to those shown in Fig.
2 for WB mushrooms (data not shown). The data suggest
that WB, crimini and shiitake mushrooms had similar
effects on cytokine production from BMDM.
Mushroom induced T cell production of cytokines
Crimini, shiitake and oyster mushrooms were used to
stimulate antigen specific T cells. T cell receptor transgenic
(OT II) mice were used as a source of antigen (ovalbumin,
OVA) specific T cells. The lymphocytes from the spleen of
OT II mice were isolated and stimulated with OVA plus
DMSO (control), or OVA plus mushrooms. In the absence
of OVA stimulation the splenocytes did not produce
cytokines. OVA stimulation (control) induced IL-10 pro-
duction that was inhibited by crimini, shitake and oyster
mushroom extracts (Fig. 3A). Conversely, interferon
(IFN)-γ secretion was induced by crimini, shiitake and
oyster mushroom extracts in two experiments and unaf-
fected by mushroom extracts in another (Fig. 3B). IL-4 was
undetectable in all of the supernatants tested. The experi-
ment was repeated using OVA stimulation alone (DMSO
control) or WB stimulation. IFN-γ secretion was 2058 ± 60
pg/ml in the controls and 2534 ± 154 pg/ml in the WB
stimulated cultures while IL-10 was 3500 ± 50 pg/ml in
the controls and 1200 ± 135 pg/ml in the WB stimulated
cultures (control IL-10 values are significantly higher thanBMC Immunology 2009, 10:12 http://www.biomedcentral.com/1471-2172/10/12
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WB IL-10 values P < 0.05). The data suggest that in these
mixed cell cultures all 4 types of mushrooms either
increased IFN-γ or had no effect. In addition, there were
no differences between the ability of the 4 types of mush-
rooms tested for inhibiting IL-10 in T cells.
Orally ingested mushrooms do not show overt toxicity or 
cytokine production ex vivo
The in vivo experiments were done primarily with WB
mushrooms and one experiment was done using oyster
mushrooms. The weight curves show that WB mushroom
containing diets (2% by weight) did not negatively affect
body weight and instead the mice continued to grow over
the 4 weeks of the study (Fig. 4A). Histopathology sec-
tions of the stomach, intestine, kidney, and liver showed
that feeding WB mushrooms for 4 weeks was not associ-
ated with any pathology in these tissues (data not shown).
Unchallenged mice had undetectable levels of TNF-α, IL-
10 and IL-1β in the colon or blood whether or not they
were fed WB mushrooms (data not shown). Splenocytes
were removed from the WB and oyster fed mice and cell
surface staining showed that there was no change in the
percentage of CD4+, CD8+, B cells, and macrophage as a
result of including mushrooms in the diet (data not
shown). The splenocytes from the WB, oyster and control
fed mice were stimulated in vitro with the T cell mitogen
concanavalin (Con) A or the macrophage/B cell mitogen
LPS. Splenocytes did not make IL-10 without further res-
timulation in vitro (Fig. 4B). Con A stimulation induced
IL-10 in cultures from all 3 groups of mice but there was
no effect on IL-10 production as a result of the mice con-
suming mushrooms (Fig. 4B). LPS stimulation induced
Production of TNF-α by RAW 264.7 cells Figure 1
Production of TNF-α by RAW 264.7 cells. Mushroom extracts (100 μg/ml), LPS or vehicle (DMSO) controls were added 
to Raw 264.7 cells and 72 h later TNF-α production was evaluated in triplicate cultures. Data from one representative of three 
individual experiments are shown. Values are mean ± SD, *p < 0.05 compared to the LPS TNF-α response.BMC Immunology 2009, 10:12 http://www.biomedcentral.com/1471-2172/10/12
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Cytokine production by primary BMDM Figure 2
Cytokine production by primary BMDM. WB mushroom extracts alone, LPS alone or WB in combination with LPS 
(WB+LPS) were added to BMDM. Supernatants were harvested 72 h later and (A) TNF-α, (B) IL-1β and (C) IL-10 were 
detected by ELISA. The data is one representative of four individual experiments. Values are mean ± SD of triplicate cultures. 
Values for WB+LPS are significantly different from LPS stimulated with the p value as shown.BMC Immunology 2009, 10:12 http://www.biomedcentral.com/1471-2172/10/12
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Mushroom mediated inhibition of IL-10 and enhancement of IFN-γ Figure 3
Mushroom mediated inhibition of IL-10 and enhancement of IFN-γ. Splenocytes from OT II mice were stimulated 
with OVA plus WB, Crimini, Shiitake, Oyster and Maitake extracts or Control (OVA plus DMSO). (A) IL-10 and (B) IFN-γ 
secretion. Representative data from two individual experiments with n = 5–6 mice each. Values are mean ± SEM. Values are 
significantly different from the control group, *p < 0.05, **p < 0.01.BMC Immunology 2009, 10:12 http://www.biomedcentral.com/1471-2172/10/12
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In vivo effects of feeding mushrooms Figure 4
In vivo effects of feeding mushrooms. C57BL/6 mice were fed control diet only or control diet that contained 2% WB 
freeze dried mushrooms. (A) Weights of the WB fed mice gained weight over the 4 weeks of the study. Values are mean ± 
SEM with 6–10 mice per group. (B) IL-10 and (C) IFN-γ production of Con A and LPS stimulated splenocytes from 1% WB fed, 
1% oyster fed and control (Ctrl) fed mice. Values are mean ± SEM with 3–5 mice per group.BMC Immunology 2009, 10:12 http://www.biomedcentral.com/1471-2172/10/12
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considerably more IL-10 than Con A but still all 3 groups
of mice produced IL-10 and there were no significant dif-
ferences across the groups (Fig. 4B). There was no detect-
able IL-12 in the Con A or LPS stimulated cultures, low
levels of TNF-α secretion and no IFN-γ production in the
LPS stimulated splenocytes. Splenocytes did not make
IFN-γ without further restimulation in vitro (data not
shown). Con A stimulated splenocytes from the control
(Ctrl), WB and Oyster treated groups produced IFN-γ (Fig.
4C) but there was no effect of WB or oyster mushrooms
compared to Ctrl treatment on the ex vivo IFN-γ response.
Dextran sodium sulfate (DSS) treatment and in vivo 
mushroom feeding
Based on the data in Fig. 2 showing the maximal effect of
WB mushrooms occurred when the BMDM are also stim-
ulated with LPS, mice were challenged in vivo with DSS.
Like LPS, DSS stimulates the innate immune system. DSS
initiates mucosal epithelial cell damage by disrupting bar-
rier function, leading to ulceration, bleeding, and tran-
sient shortening of the colon [8,9]. The damage to the gut
mucosa begins to repair following removal of the DSS
from the water. Consistent with the acute colitis induced
by DSS the control fed mice showed a drop in weight after
4 d of DSS treatment and then the mice recovered in
weight almost completely by 10 d post-DSS (Fig. 5A).
Weight loss in the oyster fed mice was not different from
the control mice (Fig. 5A). Conversely, the WB fed mice
did not lose as much weight as the other 2 groups (signif-
icantly different at d4, d5, and d6 and not different at d10,
Fig. 5A). Additional groups of mice were fed control, 1%
WB and 1% oyster diets but were not exposed to DSS. All
Mice from all three groups that were not exposed to DSS
maintained their body weight throughout the experiment
(data not shown). There was no bleeding observed in any
of the colons upon sacrifice at d10. The colons of WT mice
fed control, 1% WB or 1% oyster diets and not exposed to
DSS averaged 79 mm in each group (data not shown). Ten
d post-DSS treatment the control, WB and oyster fed mice
had colons that were not different from one another and
averaged 78–79 mm (Fig. 5B). Colonic homogenates
showed that all groups produced TNF-α, IL-1β and IL-10
but that the variability was such that there were no signif-
icant differences (Fig. 5C). Colonic homogenates from
mice that were not treated with DSS produced low levels
of TNF-α (700 pg/ml), and IL-10 (400 pg/ml, IL-1β was
undetectable) and not different in the control, WB and
oyster fed mice (data not shown).
The DSS experiment was repeated using 2% WB fed mice
and control fed mice. There was no blood in the colons of
WB or control fed mice at 5 or 10 d post-DSS (data not
shown). The colonic lengths of the control fed mice short-
ened as expected following 5 d of DSS (from 78 to 64
mm) and the WB fed colons were also shorter following 5
d of DSS (from 78 to 71 mm) however the colons from
WB fed mice were significantly longer than control at d5
post-DSS (Fig. 6A). At d 10 the WB and control colons
recovered and were not different from one another (Fig.
6A). The amount of TNF-α produced in the colon and
blood of WB fed mice was significantly higher than the
controls (Fig. 6B and 6C, respectively). Other cytokines
including IL-1β, IL-10 and IFN-γ, were not affected by WB
feeding (data not shown). Histopathology of the colon
showed no effect of WB feeding on symptoms of DSS col-
itis. WB feeding of WT mice was associated with protec-
tion from early weight loss (Fig. 5A), protection from
colonic shortening (Fig. 6A) and an increase in TNF-α
production in the serum and colon (Fig. 6B).
Discussion
The immunomodulatory or antitumor activity associated
with mushroom intake has been suggested to be due to a
number of isolated fractions from mushrooms including
the β-D-glucans, and other polysaccharides [10-13]. The
standard approach has been to purify the components
and then to test them for efficacy. It is likely that mush-
rooms possess multiple immunoregulatory components
including the selenium, B vitamins and polysaccharides
that when ingested together or mixed in vitro together
would have effects that differed from the isolated compo-
nents. In vitro WB, crimini, shiitaki, and oyster extracts
reduced IL-10 production and increased IL-1β, and TNF-α
production by macrophage. The activation of the macro-
phage with the mushroom extracts preferentially stimu-
lated T cell production of TNF-α and IFN-γ and very little
IL-10. This pattern of immuno-regulation by mushrooms
is consistent with a model whereby whole mushroom
consumption would induce a modest but important
boost in immune responses that would improve anti-can-
cer immunity (Fig. 7). In macrophage, the inhibition of
IL-10 and activation of IFN-γ, IL-1β, and TNF-α would
result in an activated phenotype for the macrophage that
would induce production of T cell and macrophage
cytokines like IFN-γ and TNF-α that are important in clear-
ance of tumorogenic cells, pro-inflammatory signaling,
and killing of infectious organisms (Fig. 7). In RAW 264.7
cells the induction of TNF-α production was highest in
LPS and WB stimulated rather than the crimini, maitake,
oyster, or shitake stimulated cells. The differences might
be a result of differences in the quantity of the immu-
nomodulatory substance or substances and or differences
in solubility of mushrooms in the DMSO used to produce
the extracts. However, the direction of the changes
(increase versus decrease) were not different among the
mushroom treatments. The lack of differential effects on
cytokine secretion by the mushroom extracts suggests that
the whole mushrooms must share a common compo-
nent(s) that act to regulate immune function.BMC Immunology 2009, 10:12 http://www.biomedcentral.com/1471-2172/10/12
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DSS challenge of 1% WB, 1% oyster and control fed mice Figure 5
DSS challenge of 1% WB, 1% oyster and control fed mice. Control, WB and oyster fed mice that were treated with 
DSS for 5 d followed by water for 5 d (10 d post-DSS). (A) Percentage of starting weight following DSS treatment, (B) colonic 
length at d 10 after DSS treatment, and (C) colonic production of TNF-α, IL-1β and IL-10 at d 10 post-DSS. Values are mean ± 
SEM of 4–6 mice per group.BMC Immunology 2009, 10:12 http://www.biomedcentral.com/1471-2172/10/12
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DSS colitis of 2% WB fed and control fed mice Figure 6
DSS colitis of 2% WB fed and control fed mice. Control, and WB fed mice were treated with DSS for 5 d (5 d post-DSS) 
followed by water for 5 d (10 d post-DSS). (A) Colonic length as a function of DSS treatment, TNF-α production at d 10 post-
DSS in the colon (B) and serum (C). Values are mean ± SEM of 4–8 mice per group. Values are significantly different from the 
control group, *p < 0.05.BMC Immunology 2009, 10:12 http://www.biomedcentral.com/1471-2172/10/12
Page 10 of 13
(page number not for citation purposes)
Feeding mice diets that included up to 2% WB mush-
rooms over 4 weeks had no effect on a number of immune
parameters including percentage of T and B cells, Con A
and LPS stimulated cytokine production and colonic
expression of a panel of cytokines including IL-1β, IL-10,
TNF-α and IFN-γ. This is consistent with data by Wu et al.
that showed that WB mushroom feeding at much higher
doses (2–10%) and for 10 weeks did not affect T cell, B
cell, NK cell, and macrophage cell numbers or affect Con
A and LPS induced cytokine production [14]. This is not
completely unexpected since it would certainly be harm-
ful to have a commonly present dietary component
induce or suppress normal immune function.
DSS is normally used to cause transient colonic injury and
as a model of acute colitis. WB feeding was protective for
some parameters of DSS colitis; early weight loss and
colonic shortening. It is unclear by what mechanism the
WB feeding would protect from colonic injury. When
challenged with DSS the WB mushroom fed animals tran-
siently produced more TNF-α in the colon but showed no
other changes in immune function. TNF-α production is
negatively associated with colitis symptoms in the DSS
model. Therefore the increased local production of TNF-α
and decreased colitis injury following WB intake are para-
doxical. The improvement in colitis symptoms is unlikely
to be related to the increased production of TNF-α but
instead might reflect a change in the composition of the
bacterial microflora that has been shown to impact dis-
ease symptoms in the DSS model [15]. The data show that
WB mushrooms are protective against colonic injury and
the mechanisms underlying the protective effects would
be an area worthy of future investigation.
Agaritine, a natural compound found in the Agaricus spe-
cies of mushrooms, has been implicated as a carcinogen
[16-18]. Even though animal studies do not show agari-
tine to be a carcinogen at physiological doses there is still
a possible concern regarding toxicity at high intake levels
of mushrooms [16-18]. WB mushrooms are Agaricus
mushrooms and are the most commonly consumed
mushrooms in the US. Toxicity might be expected in tis-
sues that come into contact with the agaritine like the
stomach or intestines and those tissues that might break
down or excrete absorbed agaratine like the liver or kid-
ney. Based on the normal growth curves of mice fed 2%
WB mushrooms for 4 weeks and data by Wu et al. show-
ing that intake as high as 10% WB mushrooms for 10
weeks did not affect body weight we can conclude that
there are no gross effects of feeding mice agaritine con-
taining mushrooms [14]. In addition, histopathology sec-
tions of the stomach, small intestine, large intestine, liver
and kidney from mice fed WB mushrooms showed no
changes that might indicate an affect of increased agari-
tine intakes over the 4 weeks of the study. While it still
might be possible that longer term intake of agaritine con-
taining mushrooms might prove toxic, the present data
using moderate doses of mushrooms does not support the
claim.
Mushrooms contain a significant amount of protein, vita-
mins and minerals in addition to a large amount of carbo-
Model of the effects of whole mushrooms on anti-cancer immunity Figure 7
Model of the effects of whole mushrooms on anti-cancer immunity. Whole mushrooms contain active components 
that can induce TNF-α, and IL-1β in vitro while inhibiting IL-10 production. Consuming mushrooms in the diet also had an effect 
on immune function but that effect is evident only when the immune system is challenged. The change in the immune response 
induced by whole mushrooms is consistent with a potentially important improvement in cancer surveillance and anti-microbial 
killing while increasing inflammation and perhaps autoimmunity.BMC Immunology 2009, 10:12 http://www.biomedcentral.com/1471-2172/10/12
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hydrate much of which are polysaccharides that are
indigestible by humans and therefore are considered die-
tary fiber [19]. It is possible that differences in the cultiva-
tion of mushrooms in different regions and by different
growers may affect the composition of an important
immunomodulatory factor. One of the limitations of the
present study is that the results presented may only reflect
results of mushrooms grown in Pennsylvania and more
specifically by the manufacturers of those mushrooms in
Pennsylvania. Future research should sample mushrooms
from different suppliers of the same species for compari-
son of immunomodulatory functions.
Several major substances have been isolated from mush-
rooms and shown to be immunomodulatory. What has
not been considered is that mushrooms have a number of
bacteria, yeasts and molds associated with them. In fact
microorganisms are required for initiation of fruit body
formation. Normal healthy mushrooms have high bacte-
rial populations associated with them with the numbers
ranging from 6.3–7.2 log CFU/g of fresh mushrooms [19].
The bacteria associated with mushrooms are predomi-
nately the pseudomonads [19-22]. The pseudomonads
have been shown to activate the innate immune response
by interactions with the Toll like receptors (TLR), espe-
cially TLR-5 [23-25]. It is likely that the microbiota
ingested with the mushrooms are triggering the mucosal
innate immune response through the TLR. More research
is required to determine the relative contributions of bac-
teria,  versus  nutrient and other components of mush-
rooms as immune system regulators.
Conclusion
Whole mushrooms have a number of components that
are potentially immuno-modulatory. The in vitro data
show that whole mushroom extracts regulate macrophage
and T cell production of cytokines in a way that is pre-
dicted to be beneficial for boosting anti-tumor immunity.
In vivo, the immuno-regulatory functions of edible mush-
rooms are harder to detect. Following challenge with DSS
there is a transient protection from colonic injury and a
modest increase in TNF-α production locally in the colon.
Whether the increase is an effect of known immuno-mod-
ulatory nutrient components or as a result of bacteria like
the psuedomonads that are associated with mushroom
cultivation is not known.
Methods
Animals
OTII (OVA specific T cell receptor transgenic) C57BL/6
and control C57BL/6 mice were bred and maintained at
the Pennsylvania State University (University Park, PA).
The mice were fed synthetic diets made in the laboratory
as described previously [26-28]. In one experimental
design the mice were either control fed or fed diets that
included 2% powdered mushrooms for 4 weeks (8–10
mice per group). In a second design mice were fed control,
1% or 2% WB or oyster mushrooms for 1 week prior to,
and continuing through the DSS treatment (4–8 mice per
group). Controls included additional mice that were fed
the same diet but were not treated with DSS (3–4 mice per
group). Experimental procedures were approved by the
Office of Research Protection, Institutional Animal Care
and Use Committee at the Pennsylvania State University.
Mushroom extracts
Commercially available and commonly consumed mush-
rooms were used for this study. Agaricus bisporous or com-
mon name WB, brown Agaricus bisporous or common
name crimini, Grifola frondosa or common name maitake,
Lentnula edodes or common name shiitake, and Pleurotus
eryngii  common name king oyster mushrooms were
obtained from Modern Mushroom Farm, Inc. (Toughken-
amon, PA). The whole mushrooms were freeze-dried and
ground into a fine powder. For the in vitro experiments, 10
mg of mushroom powder was suspended in 1 ml dime-
thyl sulfoxide (DMSO, Sigma, St. Louis, MO) and soni-
cated (Branson Ultrasonic Corporation, Danbury, CT) for
8 min at room temperature. The crude unfiltered extracts
were used for the experiments below. Mushroom extracts
were tested for LPS levels (Limulus Ameobocyte Lysate
assay, Cambrex, Walkersville, MD). There was a low level
of LPS contamination of the extracts (3 ng/ml in WB and
3.2 pg/ml or less in the other extracts). The final concen-
tration of LPS from the WB extracts added to the cultures
was 30 pg/ml LPS. This concentration of LPS was well
below the level of LPS required to stimulate cells in vitro.
Although commercially produced according to standard-
ized methods, there are likely to be important differences
between mushrooms grown in different areas and under
different conditions. Thus, freeze-dried mushrooms and
extracts will be provided upon request.
Cell cultures
RAW 264.7 cells were obtained from ATCC (Manassas,
VA) and 106 cells per well were cultured in the presence of
100 μg of mushroom extracts or equal concentrations of
DMSO (0.1 μl/ml) alone for 72 h in Dulbecco's modified
Eagle's medium (Sigma) supplemented with 10% fetal
calf serum (FCS), 100 U/L penicillin, 100 mg/L strepto-
mycin and 4 mmol/L glutamine (Invitrogen, Carlsbad,
CA). Viability of the cultures after the 72 h was checked by
trypan blue exclusion and was not different between the
cells that received mushroom extract, DMSO or just
media.
BMDM were obtained as previously described [29].
BMDM from five C57BL/6 mice were pooled and cultured
for 7 d at 37°C in the presence of recombinant macro-
phage colony-stimulating factor (R&D Systems, Minneap-BMC Immunology 2009, 10:12 http://www.biomedcentral.com/1471-2172/10/12
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olis, MN), in cold DMEM medium containing 25 mmol/
L HEPES, 2 mmol/L glutamine, 5 × 10-5 mol/L 2-mercap-
toethanol, 100 U/L penicillin and 100 mg/L streptomy-
cin, supplemented with 100 ml/L FCS. More than 90% of
the cells had macrophage morphology (large cells with
irregular outlines, abundant cytoplasm and oval or
indented nucleus) as determined by viewing cytospin
preparations and by flow cytometry (F480 and CD11b
positive). After 7 d in culture, the BMDM were washed
with phosphate-buffered saline (PBS) and cells were cul-
tured (106 cell/well) in the presence of mushroom extracts
(100  μg/ml) alone, LPS (0.5 μg/ml, Sigma) alone, or
mushroom extracts plus LPS for 72 h. Cell viability was
checked at 72 h (trypan blue exclusion) and found not to
be different among the different treatment groups.
Splenocyte suspensions from OT II mice were prepared
and placed (106  cell/well) in complete RPMI 1640
(Sigma) medium-supplemented with 100 ml/L FCS,
mmol/L HEPES, 2 mmol/L glutamine, 100 U/L penicillin
and 100 mg/L streptomycin (Invitrogen, Gibco). Spleno-
cytes in 24-well culture plates (Becton Dickinson
Labware, Franklin Lakes, NJ) were cultured in the pres-
ence of crimini, shiitake, or oyster (100 μg/ml) and OVA
(1 mg/ml, Sigma) or OVA alone for 72 h. In a separate
series of experiments OT II splenocytes were cultured with
WB (100 μg/ml) and OVA (1 mg/ml, Sigma) stimulation
or OVA alone for 72 h. Cell viability was checked at 72 h
(trypan blue exclusion) and found not to be different
among the different treatment groups.
Splenocytes suspensions from C67BL/6 mice were pre-
pared and 106 cells/well were placed in complete RPMI
1640. Splenocytes were cultured with LPS, 0.5 μg/ml),
Con A (10 μg/ml) or media for 72 h when supernatants
were collected for the detection of cytokines by enzyme-
linked immunosorbent assay (ELISA). Cell viability was
checked at 72 h (trypan blue exclusion) and found not to
be different among the different treatment groups.
DSS challenge
Mice were administered 3.5% DSS (MW = 40 kDa; ICN
Biomedicals, Solon, OH) dissolved in filter-purified and
sterilized water ad libitum for 5 d followed by a return to
water for the remainder of the experiment (10 d following
the start of DSS treatment).
Colon measurements
The gross colonic blood scoring system previously
described by Siegmund et al[30] was used. The entire
colon from cecum to anus was removed and the length
was measured and reported as colonic length as described
[8].
The distal colon was weighed and the same amount of tis-
sue was cut open and washed in 1 × PBS containing peni-
cillin (100 U/ml) and streptomycin (100 mg/ml). Tissue
was then scrapped in 1 ml PBS using a razor blade. The
colon tissue scrapings were centrifuged at 10,000 g at 4°C
for 10 min. Cytokine concentrations in the supernatant of
the colonic homogenate were measured by ELISA.
Histopathology
Parts of the stomach, intestine, kidney, and liver were
saved in 10% formalin and sent to the Pennsylvania State
Diagnostic Laboratories (University Park, PA) for staining
(hematoxilyn and eosin) and evaluation of the tissue sec-
tions. The distal colon were removed from mice treated
with DSS and histological analysis was performed blinded
for pathology associated with DSS treatment as described
[9].
Cytokine detection
ELISA kits (Pharmingen, San Diego, CA) were used to
determine the levels of IFN-γ, IL-10, IL-1β, TNF-α, IL-4
and IL-12 in the supernatants, serum and colonic
homogenates. The limits of detection were 125 pg/ml
IFN-γ, 31.25 pg/ml IL-10, 31.25 pg/ml IL-1β, 31.25 pg/ml
TNF-α, 31 pg/ml IL-4 and 125 pg/ml IL-12 p70.
Statistical analysis
Statistical analyses were performed using PRISM software
(GraphPad Software, San Diego, CA) using ANOVAs and
data that were not normally distributed were transformed
prior to ANOVA. P values of 0.05 or less were considered
statistically significant.
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